Target Name: DDAH1
NCBI ID: G23576
Other Name(s): DDAH1 variant 1 | N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 (isoform 2) | Dimethylarginine dimethylaminohydrolase 1, transcript variant 1 | DDAHI | Dimethylargininase 1 | DDAH-1 | Dimethylarginine dimethylaminohydrolase 1 | Dimethylargininase-1 | DDAH1 variant 2 | Epididymis secretory protein Li 16 | dimethylarginine dimethylaminohydrolase 1 | Dimethylarginine dimethylaminohydrolase 1, transcript variant 2 | epididymis secretory protein Li 16 | dimethylargininase-1 | DDAH | N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 | NG, NG-dimethylarginine dimethylaminohydrolase | DDAH1_HUMAN | HEL-S-16 | N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 (isoform 1)

Overview of DDAH1: A Potential Drug Target and Biomarker

DDAH1 (DDAH1 variant 1) is a gene that encodes for a protein known as DDAH1. DDAH1 is a member of the DDAH gene family, which is characterized by the presence of a conserved domain called the N-terminal alpha-helicase domain. This domain is known to be involved in the detoxification of xenobiotics, such as drugs and environmental toxins, by the liver.

Recent studies have identified DDAH1 as a potential drug target and biomarker for several diseases, including drug addiction, alcoholism, and neurodegenerative disorders. In this article, we will provide an overview of DDAH1, including its structure, function, and potential as a drug target and biomarker.

Structure and Function

The N-terminal alpha-helicase domain of DDAH1 is a structural feature that is unique among proteins. It consists of a Rossmann-fold, a type of protein fold that is characterized by a specific arrangement of secondary structure elements. The Rossmann-fold is responsible for the formation of the N-end region of the protein, which is involved in the formation of the protein-protein interaction.

The function of DDAH1 is closely tied to its structure. DDAH1 is involved in the detoxification of xenobiotics by the liver. Xenobiotics are molecules that are foreign to the body and can be harmful to the body's delicate systems. DDAH1 is the enzyme that is responsible for breaking down these xenobiotics to produce less toxic compounds.

DDAH1 is also involved in the detoxification of drugs that are harmful to the liver. Many drugs are metabolized by the liver and can be harmful if they are not properly detoxified. DDAH1 is the enzyme that is responsible for breaking down these drugs to produce less toxic compounds.

DDAH1 is also involved in the detoxification of environmental toxins, such as arsenic and lead. These toxins can be found in natural environments and can be harmful to the body if they are not properly detoxified. DDAH1 is the enzyme that is responsible for breaking down these toxins to produce less toxic compounds.

Potential as a Drug Target

DDAH1 has been identified as a potential drug target for several reasons. One reason is that it is involved in the detoxification of xenobiotics, which are molecules that are foreign to the body and can be harmful to the body's delicate systems. Many drugs are metabolized by the liver and can be harmful if they are not properly detoxified. DDAH1 is the enzyme that is responsible for breaking down these drugs to produce less toxic compounds.

Another reason why DDAH1 has been identified as a potential drug target is that it is involved in the detoxification of environmental toxins, such as arsenic and lead. These toxins can be found in natural environments and can be harmful to the body if they are not properly detoxified. DDAH1 is the enzyme that is responsible for breaking down these toxins to produce less toxic compounds.

In addition, DDAH1 is a conserved protein, which means that it is similar to other proteins that are found in the body. This conserved nature makes it an attractive target for researchers to study and identify new drugs that can interact with DDAH1.

Potential as a Biomarker

DDAH1 has also been identified as a potential biomarker for several diseases, including drug addiction, alcoholism, and neurodegenerative disorders. One reason for this is that DDAH1 is involved in the detoxification of many of the drugs that are associated with these diseases. For

Protein Name: Dimethylarginine Dimethylaminohydrolase 1

Functions: Hydrolyzes N(G),N(G)-dimethyl-L-arginine (ADMA) and N(G)-monomethyl-L-arginine (MMA) which act as inhibitors of NOS. Has therefore a role in the regulation of nitric oxide generation

More Common Targets

DDAH2 | DDB1 | DDB2 | DDC | DDC-AS1 | DDD core complex | DDHD1 | DDHD2 | DDI1 | DDI2 | DDIAS | DDIT3 | DDIT4 | DDIT4L | DDN | DDO | DDOST | DDR1 | DDR2 | DDRGK1 | DDT | DDTL | DDX1 | DDX10 | DDX11 | DDX11-AS1 | DDX11L1 | DDX11L10 | DDX11L2 | DDX11L8 | DDX11L9 | DDX12P | DDX17 | DDX18 | DDX18P1 | DDX19A | DDX19A-DT | DDX19B | DDX20 | DDX21 | DDX23 | DDX24 | DDX25 | DDX27 | DDX28 | DDX31 | DDX39A | DDX39B | DDX39B-AS1 | DDX3P1 | DDX3X | DDX3Y | DDX4 | DDX41 | DDX42 | DDX43 | DDX46 | DDX47 | DDX49 | DDX5 | DDX50 | DDX50P1 | DDX51 | DDX52 | DDX53 | DDX54 | DDX55 | DDX56 | DDX59 | DDX59-AS1 | DDX6 | DDX60 | DDX60L | DDX6P1 | DEAF1 | Death-associated protein kinase | Decapping Complex | DECR1 | DECR2 | DEDD | DEDD2 | Dedicator of cytokinesis protein | DEF6 | DEF8 | DEFA1 | DEFA10P | DEFA11P | DEFA1B | DEFA3 | DEFA4 | DEFA5 | DEFA6 | DEFA7P | DEFA8P | DEFA9P | DEFB1 | DEFB103A | DEFB103B | DEFB104A | DEFB104B